AllDocs -> cancers

HERA Ovarian Cancer Climb for Life | http://ovariancancer.jhmi.edu/climb Where the Money Goes: Conquering Ovarian Cancer One Foot at a Time THE NEED q Ovarian cancer is not an uncommon disease. It is the 5th leading cause of cancer death among women and kills more women than all the other reproductive cancers combined. q 90% of women who get the disease have no family history q According to a recent study published in England, ovarian cancer is on the rise in younger women. q There is not a reliable test for ovarian cancer like the pap smear for cervical cancer or the mammogram for breast cancer . Over 78% of the women diagnosed in 2004 will be diagnosed after the disease has spread when the chance for survival is less than 20%. When ovarian cancer is caught early it is highly ...

Ovarian cancer is a serious and under-recognized threat to women’s health. • Ovarian cancer , the deadliest of the gynecologic cancers, is the fourth leading cause of cancer death among women living in the U.S. • Ovarian cancer occurs in 1 out of 57 women. • It is expected that 25,580 women will be diagnosed with the disease in 2004. • An estimated 16,090 American women will die from ovarian cancer in 2004. Ovarian cancer is very treatable when it is detected early, but the vast majority of cases are not diagnosed until the cancer has spread beyond the ovaries. • Ovarian cancer may be difficult to diagnose because symptoms are sometimes subtle and may be easily confused with those of other diseases. • In cases where ovarian cancer is detected before it has spread beyond the ovaries, more than 95% of women will survive longer than ...

OVARIAN CANCER NATIONAL ALLIANCE Statement on OvaCheck™ and Other Proteomics Tests February 8, 2004 The Ovarian Cancer National Alliance believes that proteomics technology is an exciting and promising development that is likely to provide great benefits for screening, increased early detection, and improved treatments for ovarian cancer . Particularly for women at high risk of developing ovarian cancer and the physicians who care for them, we see OvaCheck™ as a potentially promising tool. We are mindful 16,000 women will die of ovarian cancer this year, and more than 25,000 new cases will be diagnosed – three-quarters of them with advanced stage disease when five-year survival rates are lowest. For this reason, we urge the researchers, scientists and clinicians who are engaged in seeking to validate OvaCheck™, and any other proteomics tests being developed ...

MDACC INITIAL EVALUATION Epithelial Ovarian Cancer (Page 1 of 2) Pelvic Mass Diagnosis by previous surgery CXR CA125 Ultrasound or CT of abdo- men and pelvis if clinically indicated CXR Verify most recent mammogram CA125 Ultrasound or CT of abdomen and pelvis if suspicion of cancer Barium enema if clinically indicated Laparotomy/ TAH/BSO with comprehensive staging, or If Stage I, Grade 1 and patient desires fertility - USO and staging biopsies, or If Stage III or IV and medically stable - cytoreductive surgery, or If patient unable to tolerate surgery, consider chemotherapy. Appropriate surgery and staging PRIMARY TREATMENT CLINICAL PRESENTATION Options based on individual patient characteristics: ...

FOR IMMEDIATE RELEASE Contact: Chintimini M. Notton February 12, 2004 202.331.1332 ext 305 cnotton@ovariancancer.org Ovarian Cancer National Alliance Elects New Leadership for 2004 Washington, DC (February 12, 2004) – The Ovarian Cancer National Alliance announced its new executive Board for 2004. Ginger Ackerman Smith will serve as president of the Alliance. Ackerman Smith, who resides in Atlanta, is the founder and past president of the Georgia Ovarian Cancer Alliance and a seven-year survivor of ovarian cancer . Her professional experience includes financial consulting, marketing and political activism. Ackerman Smith has also served as a peer reviewer for the Department of Defense. “I am delighted and honored to lead this organization in accomplishing our goal of educating all women about ovarian cancer , and ultimately saving lives. As we look ...

Ovarian Cancer Trials at RPCI Two new ovarian cancer prevention trials are accruing patients at RPCI. Initally, women in the Gilda Radner Familial Ovarian Cancer Registry were invited to participate, but any woman with an increased risk of ovarian cancer (either due to family history or previous use of fertility medication) may be eligible. Your patients may contact 1-877-ASK-RPCI (1-877- 275-7724) for more information. The first is a chemoprevention trial offered through the Gynecologic Oncology Group (GOG). It involves the use of a potential ovarian cancer preventive drug called fenretinide. Preliminary data indicate that fenretinide may delay or perhaps prevent the onset of ovarian cancer . The trial is open to women with a family history of ovarian cancer who are considering having their ovaries removed as a means to lower their ...

Background Information on the PROTEOMIC SCREENING TEST FOR OVARIAN CANCER January 23, 2004 Media reports concerning the OvaCheck test have generated a great deal of interest in the subject of early detection of ovarian cancer . The Ovarian Cancer National Alliance, our partner members around the country, and women everywhere have long awaited the development of a simple and reliable screening test for ovarian cancer . The news that at least one such test is expected in early 2004 is extremely exciting, because if this screening process lives up to expectations, it has the potential to save tens of thousands of women’s lives. This breakthrough methodology for detecting ovarian cancer in its earliest stages – when it is most treatable and survival rates are highest – relies on a simple blood test. While all the specific details are not yet known, some common questions ...

FOR IMMEDIATE RELEASE 03/10/03 For more information: shughes@wellnesscommunitytn.org FREE Workshop for Women Living with Ovarian Cancer Brought to you by The Wellness Community Knoxville, TN (March 10, 2003) – The Wellness Community, a national non-profit organization based in Knoxville, will be offering the first program of its kind for women living with ovarian cancer . This FREE “Patient Active Guide to Living with Ovarian Cancer ” will explore new ways to improve the quality of life during and after treatment by discussing ways to empower women to take a proactive approach to fighting the disease. The Patient Active Guide to Living with Ovarian Cancer will be held Saturday, March 22, 2003 from 10:00am to 12-noon and feature speaker, Dennis Scribner, Jr., M.D., a gynecologic oncologist from Southeast Gynecologic Oncology ...

a report by B r i s t o l - M y e r s S q u i b b C o m p a n y Survival from ovarian cancer has increased over time mainly due to improvements in diagnosis, surgery and chemotherapy but, despite these advances, it remains the second most common and deadly form of gynaecological cancer with an overall five-year survival rate of less than 50%. 1 The evolution of chemotherapy regimens from standard platinum- based first-line chemotherapy to Taxol ® (paclitaxel) and cisplatin * as the standard of care has undoubtedly played a huge part in shaping a better landscape for women with this disease. We are all too aware of the devastating impact that any cancer has on the lives patients and their families, but ovarian cancer in particular can take everyone by surprise due to vague or silent symptoms associated ...

BRCA and Breast/ Ovarian Cancer -- Disorder/Setting Version 2003-6 1-1 DISORDER/SETTING Question 1: What is the specific clinical disorder to be studied? Question 2: What are the clinical findings defining this disorder? Question 3: What is the clinical setting in which the test is to be performed? Question 4: What DNA test(s) are associated with this disorder? Question 5: Are preliminary screening questions employed? Question 6: Is it a stand-alone test or is it one of a series of tests? Question 7: If it is part of a series of screening tests, are all tests performed in all instances (parallel) or are some tests performed only on the basis of other results (series)? Page 2 BRCA and Breast/ Ovarian Cancer -- Disorder/Setting Version 2003-6 1-2 DISORDER/SETTING Question 1: What is the specific clinical disorder being studied? ...

BRCA and Breast/ Ovarian Cancer -- Analytic Validity Version 2003-6 2-1 ANALYTIC VALIDITY Question 8: Is the test qualitative or quantitative? Question 9: How often is a test positive when a mutation is present (analytic sensitivity)? Question 10: How often is the test negative when a mutation is not present (analytic sensitivity)? Question 11: Is an internal quality control program defined and externally monitored? Question 12: Have repeated measurements been made on specimens? Question 13. What is the within- and between-laboratory precision? Question 14: If appropriate, how is confirmatory testing performed to resolve false positives in a timely manner? Question 15: What range of patient specimens have been tested? Question 16: How often does the test fail to give a useable result? Question 17: How similar are results obtained in multiple laboratories using the same, or different, ...

New and Emerging Technology Briefing Gemcitabine for recurrent ovarian cancer July 2003 Horizon Scanning Review Early assessments of new or emerging technologies contain time-limited information and should be used with due caution. Not to be used for commercial purposes National Horizon Scanning Centre Page 2 National Horizon Scanning Centre GEMCITABINE in Ovarian Cancer July 2003 1 Gemcitabine for recurrent ovarian cancer Summary Gemcitabine (Gemzar) in combination with carboplatin (Paraplatin) is in phase III clinical trials for women with recurrent ovarian cancer who have failed prior platinum-based therapy at least 6 months after discontinuation. A phase III trial has been completed but no results are yet available. A published ...

What you need to know Ovarian Cancer E ven though we hear about cancer almost every day, when you are diagnosed with cancer you may feel alone and afraid. You may also feel overwhelmed by all the infor- mation you are given and by the need to make so many decisions. This publication will give you and your family introductory information you need when you first learn that you have ovarian cancer . It will help you gain a sense of control and help you work with your healthcare team to choose the best treatments for you. Let’s Make Cancer History 1 888 939–3333 | w w w. c a n c e r. c a | Forward > 526.PDF_Ovarian_final 12/14/01 10:30 AM Page 1 Page 2 What is cancer ? Cancer is a disease that starts in our cells . Our bodies are made up of millions ...

Genetic Counseling for Breast and Ovarian Cancer Genes are found in every cell of the body and make up the basic biological unit for guiding our physical growth and development. In addition, genes are responsible for passing on hereditary information from one generation to the next. When a new child is born, he or she inherits genetic material from both the mother and the father. Unfortunately, some families carry certain genes that have been altered or changed over time and do not work as well. In some cases, these changed genes may lead to a higher chance for an individual to develop certain diseases, including breast cancer and ovarian cancer . Examples of some of these genes are "breast cancer susceptibility genes," or BRCA. So far, only two hereditary breast cancer genes, BRCA-1 and BRCA-2, have been found. With more research, new BRCA genes may be identified. As with other genes, ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Ovarian Cancer and Exposure to Ionizing Radiation 1 Ovarian Cancer and Exposure to Ionizing Radiation Summary : There has been moderately strong evidence recorded of a possible connection between ovarian cancer and exposure to ionizing radiation. This possible connection is supported by evidence from studies conducted at Los Alamos National Laboratory and other studies of nuclear workers at other sites who have been exposed to ionizing radiation. The National Research Council’s has determined that there is evidence among atomic bomb survivors of ovarian cancer in connection with exposure to ionizing radiation. Ovarian cancers are designated as “specified” cancers under the Energy Employees Occupational Illness Compensation Program ...

Last revised: 11/05/2003 UM Comprehensive Cancer Center Patient Education Document #0036 Nov03 Ed. Online version: http://www. cancer .med.umich.edu/learn/percpathways.htm University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Ovarian Cancer The purpose of this information guide is to help patients newly diagnosed with ovarian cancer and their families to find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center (PERC) of the University of Michigan Comprehensive Cancer Center in room B1-361. Brochures Available free at the Patient Education Resource Center on Level B-1 National Cancer Institute. ...

New and Emerging Technology Briefing 90 Y-muHMFG1 for ovarian cancer July 2003 Horizon Scanning Review Early assessments of new or emerging technologies contain time-limited information and should be used with due caution. Not to be used for commercial purposes National Horizon Scanning Centre Page 2 National Horizon Scanning Centre 90 Y-muHMFG1 July 2003 1 90 Y-muHMFG1 for ovarian cancer Summary 90 Y-muHMFG1 consists of a murine monoclonal antibody (HMFG1) chemically linked to the radioactive isotope yttrium-90. HMFG1 targets and binds to a tumour antigen expressed on the surface of epithelial tumour cells. R1549 (a 90 Y-muHMFG1 commercial product from Antisoma and Roche) is currently ...

ovarian cancer Nutritional Supplementation and Fatigue in an Ovarian Cancer Patient Lisa Colodny, Pharm D., BCNSP Abstract Fatigue associated with chemotherapy can range from mild to severe depending on the regimen administered and the specific type of cancer . The etiology of fatigue is not well understood and many causes are proposed including a deficiency in the body to effectively utilize dietary nutrients. Therefore, the case of a 47 year old female recently diagnosed with Stage I ovarian carcinoma for which she received chemotherapy along with dietary supplementation was reviewed. Baseline fatigue levels were obtained prior to initiation of nutritional therapy and monitored for at least 3 months. During the treatment and supplement period, significant improvement in fatigue, nausea, vomiting, diarrhea, and over all general well being was reported. Additionally, hematological monitors and cancer ...

The Ovarian Cancer National Alliance’s Annual Advocacy Conference has become THE PREMIER EVENT in the ovarian cancer survivor community, drawing over 300 advocates from across the country each year. The 2004 Conference will take place in Washington, DC at the Loews L’Enfant Plaza Hotel on September 30- October 2. As always, the Conference presenters will represent the cream-of-the crop ovarian cancer researchers and cancer care providers, distinguished scholars, policy makers as well as representatives from local and federal health care agencies. The agenda will follow the following four tracks, with breakout sessions and workshops designed to offer more in-depth coverage of specific issues. Survivorship will focus on health and well being of women facing, battling or surviving ovarian cancer . We will discuss the management of treatment side effects, clinical trials, ...

Ovarian Cancer Product List by Organization Provided by Page 2 You were just diagnosed with ovarian cancer . Where do you turn? Numerous organizations are committed to informing, helping and supporting the over 25,000 women diagnosed with ovarian cancer each year. You will be offered a vast amount of information regarding the diagnosis, treatment and survivorship from family, friends and medical professionals. With so much information out there, how can you ensure you are getting exactly what you want and need? To sort through all of the information and help you identify the important data, the Gynecologic Cancer Foundation has created this user-friendly resource guide to summarize the information, prod- ucts and materials offered by leading ovarian cancer organizations. This patient directed non-product biased list includes national ...

O va r ian C a n ce r P r og ra m 1 Ovarian Cancer Program Page 2 O va r ian C a n ce r P r og ra m 2 Part 1 – Establishment of the Ovarian Cancer Program Improving outcomes from ovarian cancer has been recognised as a priority in Australia. Ovarian cancer is the leading cause of death from gynaecological cancers in women in Australia. Each year about 1200 women in Australia are diagnosed with ovarian cancer and about 770 women will die from the disease. A new initiative In September 2001, the Commonwealth Government announced the establishment of a new program in ovarian cancer . Funds of $500,000 over two years were provided to support the program and the National Breast Cancer Centre (Centre) was asked to implement the program. The Board of the National ...

Priority actions for ovarian cancer control: a framework for a national approach. April 2002 Page 2 P r i o r i ty a c t ion s f or o va r ian ca n ce r co n tr o l : a f ra m ewo r k f o r a n at io na l a pp r oa ch 1 Foreword Ovarian cancer is the leading cause of death from gynaecological cancers in Australia. Health care professionals and consumers have identified a number of opportunities for improvement in ovarian cancer control. Priority actions for ovarian cancer control: a framework for a national approach was developed by the National Breast Cancer Centre following an extensive process of consultation with over 50 key stakeholders across Australia. It identifies a number of priority actions which are seen as being important for ovarian cancer control. This document is presented ...

O v a r i a n c a n c e r I n A u s t r a l i a n w o m e n 1 Ovarian cancer in Australian women Anne Kricker National Ovarian Cancer Centre February 2002 Page 2 2 Acknowledgements We would like to thank Professor Bruce Armstrong, Professor Neville Hacker, Dr Ian Hammond, Dr David Roder and Ms Elizabeth Tracey for reviewing a draft of this report. Page 3 O v a r i a n c a n c e r I n A u s t r a l i a n w o m e n 3 Contents Impact of ovarian cancer in Australian women 5 Incidence and mortality in Australian women 8 Age-specific incidence and mortality 9 Incidence and mortality trends in 1983-1998 10 Commonly occurring cancers in 1998 11 Most commonly occurring cancers in Australian women in 1998 ...

ovarian cancer Post Treatment Surveillance for Women with Epithelial Ovarian Cancer Goal: Surveillance is meant to identify recurrence. There are treatment options for recurrent disease though they are not curative. Early detection of recurrence does not change outcome. Therefore surveillance should be flexible. These guidelines apply to women who have completed primary therapy (surgery with removal of both ovaries plus Platinum based chemotherapy) and are without evidence of disease. Germ cell tumors and stromal tumors of the ovary are rare and have different treatment options as well as different serum markers. Those patients will require modification of the guideline. Borderline tumors of the ovary have a better prognosis and are treated surgically both for primary and recurrent disease. Effective treatment for recurrence raises the value of surveillance for these patients. Patients ...

Post Treatment Surveillance for Women with Epithelial Ovarian Cancer Goal: Surveillance is meant to identify recurrence. There are treatment options for recurrent disease though they are not curative. Early detection of recurrence does not change outcome. Therefore surveillance should be flexible. • These guidelines apply to women who have completed primary therapy (surgery with removal of both ovaries plus Platinum based chemotherapy) and are without evidence of disease. • Germ cell tumors and stromal tumors of the ovary are rare and have different treatment options as well as different serum markers. Those patients will require modification of the guideline. • Borderline tumors of the ovary have a better prognosis and are treated surgically both for primary and recurrent disease. Effective treatment for recurrence raises the value of surveillance for these patients. ...

Access to Specialty Care for Women with Ovarian Cancer : Why Gynecologic Oncologists Are Essential to the Survival of These Women Each year, approximately 24,000 women are diagnosed with ovarian cancer , and an estimated 14,000 women die of the disease. Nearly fifty percent of women die within five years, an unacceptably high mortality rate that can in part be mitigated by access to proper specialty care. Over the past two decades, research has shown that surgery by gynecologic oncologist is one of the top factors in increasing ovarian cancer survival rates, as well as decreasing rates of recurrence. Based on these findings, the Ovarian Cancer National Alliance strongly recommends that women suspected of having ovarian cancer have their surgery performed by a gynecologic oncologist. What is a Gynecologic Oncologist? A gynecologic oncologist is an obstetrician/gynecologist ...

SURVIVORS TEACHING STUDENTS: SAVING WOMEN’S LIVES An Ovarian Cancer National Alliance Project INTRODUCTION The Ovarian Cancer National Alliance has embarked on an innovative educational program for medical students in New York City. The project, “Survivors Teaching Students: Saving Women’s Lives” is designed to use ovarian cancer survivor stories to educate medical students about ovarian cancer , the deadliest of gynecologic cancer , so they are better equipped to detect the disease in early stage when it is most treatable. This project is part of the Alliance’s larger public education mission that targets consumers and health care providers around the country to increase ovarian cancer awareness. The project builds on the Alliance’s extensive experience and a highly successful speakers’ bureau. Partnerships are formed with the medical students in their learning ...

Ovarian Cervical Uterine/Endometrial Breast Incidence: 2003 1 25,400 12,200 40,100 211,300 Relative Incidence 1 • 1 in 57 2 • Ranks 2 nd among gynecologic cancers • 4% of all cancers among women • incidence rates declined slightly during 1991-1997 • Steadily decreasing incidence • With increased prevalence of Pap screening, preinvasive lesions are detected more frequently than invasive cancer • Most common of the cancers of the female reproductive tract 2 • Incidence rates higher among white women (22.6 per 100,000) than among black women (15.3 per 100,000) • 1 in 8 • Incidence rates may continue to increase slightly in white women • Increased detection of ...

Composite • Your risk increases if you have had breast cancer , or if you have a family history of breast, colorectal or ovarian cancer . How can I detect ovarian cancer early? • If you are 18-40 have a pelvic exam (recto- vaginal) by your doctor every 1-3 years. • If you are over 40 have a yearly check up with pelvic exam (recto-vaginal). • Pap tests are useful in finding cervical cancer , but they rarely find early ovarian cancer . • Talk to a doctor if you have any symptoms or signs that suggest ovarian cancer . You may want to request that your doctor order tests. These tests are not recommended for routine screening. The tests may include: ~ Ultrasound (transvaginal). ~ A special blood test called CA 125 that checks for ovarian cancer tumors. ...

ovarian cancer Ovarian Cancer 2003 Statistics 4% of all cancers in women; ranks 2nd among gynecologic cancers 25,400 new cases 25% new cases are localized disease 14,300 deaths 1 year survival rates: 80% all stages 5 year survival rates: 53% all stages; 95% local; 81% regional; 31% distant 2003 Cancer Facts & Figures, American Cancer Society Common Problems with Advanced Ovarian Cancer Ascites Intestinal obstruction (small and large bowel) Pleural effusion Malnutrition Bowel/bladder dysfunction Fluid and electrolyte imbalance Ovarian Carcinoma: Treatment Phases Symptoms Diagnosis Chemotherapy #1 Surgical Management Evaluation ? SLL Progression Chemo #2 ...